173 related articles for article (PubMed ID: 16150811)
41. Where are we with postmenopausal hormone therapy in 2005?
Lam PM; Chung TK; Haines C
Gynecol Endocrinol; 2005 Nov; 21(5):248-56. PubMed ID: 16373243
[TBL] [Abstract][Full Text] [Related]
42. Unopposed estrogen therapy and the risk of invasive breast cancer.
Chen WY; Manson JE; Hankinson SE; Rosner B; Holmes MD; Willett WC; Colditz GA
Arch Intern Med; 2006 May; 166(9):1027-32. PubMed ID: 16682578
[TBL] [Abstract][Full Text] [Related]
43. Different menopausal hormone regimens and risk of breast cancer.
Brusselaers N; Tamimi RM; Konings P; Rosner B; Adami HO; Lagergren J
Ann Oncol; 2018 Aug; 29(8):1771-1776. PubMed ID: 29917061
[TBL] [Abstract][Full Text] [Related]
44. Postmenopausal testosterone therapy and breast cancer risk.
Somboonporn W; Davis SR
Maturitas; 2004 Dec; 49(4):267-75. PubMed ID: 15531122
[TBL] [Abstract][Full Text] [Related]
45. [Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)?].
Ringa V; Fournier A
Rev Epidemiol Sante Publique; 2008 Oct; 56(5):297-301. PubMed ID: 18947946
[No Abstract] [Full Text] [Related]
46. The World Health Organization defines hormone replacement therapy as carcinogenic: is this plausible?
Mueck AO; Seeger H
Gynecol Endocrinol; 2008 Mar; 24(3):129-32. PubMed ID: 18335326
[TBL] [Abstract][Full Text] [Related]
47. Options for hormone therapy in women who have had a hysterectomy.
Haney AF; Wild RA
Menopause; 2007; 14(3 Pt 2):592-7; quiz 598-9. PubMed ID: 17476150
[TBL] [Abstract][Full Text] [Related]
48. Rationale for use of lower estrogen doses for postmenopausal hormone therapy.
Ettinger B
Maturitas; 2007 May; 57(1):81-4. PubMed ID: 17383126
[TBL] [Abstract][Full Text] [Related]
49. The medical management of menopause: to treat or not to treat?
Barlow DH
Ann N Y Acad Sci; 2008 Apr; 1127():134-9. PubMed ID: 18443341
[TBL] [Abstract][Full Text] [Related]
50. [Hormone replacement therapy].
Nozue E
Nihon Rinsho; 1994 Mar; 52(3):787-92. PubMed ID: 8164383
[TBL] [Abstract][Full Text] [Related]
51. The role of mammographic density in evaluating changes in breast cancer risk.
Pike MC
Gynecol Endocrinol; 2005 Jul; 21 Suppl 1():1-5. PubMed ID: 16112948
[TBL] [Abstract][Full Text] [Related]
52. Risk of breast cancer among users of estrogen plus progestogen and unopposed estrogen: is the likelihood of bias symmetrical?
Shapiro S
Climacteric; 2015 Jun; 18(3):333-5. PubMed ID: 25651904
[No Abstract] [Full Text] [Related]
53. The risk of breast, endometrial and ovarian cancer in users of hormonal preparations.
Bernstein L
Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):288-96. PubMed ID: 16611204
[TBL] [Abstract][Full Text] [Related]
54. The Million Women Study: a licence to kill other investigations?
van der Mooren MJ; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 2004 Mar; 113(1):3-5. PubMed ID: 15036701
[TBL] [Abstract][Full Text] [Related]
55. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
[TBL] [Abstract][Full Text] [Related]
56. Impact of hormone therapy on quality of life after menopause.
Utian WH; Woods NF
Menopause; 2013 Oct; 20(10):1098-105. PubMed ID: 23799357
[TBL] [Abstract][Full Text] [Related]
57. Postmenopausal hormones and coronary artery disease: potential benefits and risks.
Lobo RA
Climacteric; 2007 Oct; 10 Suppl 2():21-6. PubMed ID: 17882668
[TBL] [Abstract][Full Text] [Related]
58. [New SBU-report on estrogen replacement therapy in climacteric. Moderate risk of breast cancer after long-term use].
Lakartidningen; 2002 Jul; 99(28-29):3031-4. PubMed ID: 12170514
[TBL] [Abstract][Full Text] [Related]
59. Hormone therapy: maximizing the benefits.
Heikkinen J
Gynecol Endocrinol; 2006 Mar; 22(3):160-2. PubMed ID: 16835079
[TBL] [Abstract][Full Text] [Related]
60. The role of menopausal hormone therapy in preventing osteoporotic fractures: a critical review of the clinical evidence.
Col NF; Bowlby LA; McGarry K
Minerva Med; 2005 Oct; 96(5):331-42. PubMed ID: 16227948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
